Gyre Therapeutics News

Gyre Therapeutics Gets Investigational New Drug Application Approval in China for Pulmonary Arterial Hypertension Therapy

Gyre Therapeutics (GYRE) said late Thursday that the Chinese National Medical Products Administration approved its subsidiary Gyre Pharmaceuticals' investigational new drug application for F230, its t

MT NewswiresMay 31 04:28 ET

Express News | Gyre Therapeutics Inc: Receives Ind Approval From China's Nmpa to Evaluate F230 for Treatment of Pulmonary Arterial Hypertension

ReutersMay 30 16:25 ET

Express News | Gyre Therapeutics Files for Mixed Shelf Offering for $150 Mln - SEC Filing

ReutersMay 30 16:08 ET

Express News | Gyre Therapeutics Inc Files for Shelf of up to 1.1 Mln Shares of Common Stock by Selling Stockholder - SEC Filing

ReutersMay 30 16:05 ET

Gyre Pharmaceuticals Receives IND Approval From China's NMPA to Evaluate F230 for the Treatment of Pulmonary Arterial Hypertension

SAN DIEGO, May 30, 2024 (GLOBE NEWSWIRE) -- Gyre Therapeutics ("Gyre") (NASDAQ:GYRE), a clinical-stage, self-sustainable biotechnology company developing anti-fibrotic therapeutics for a variety of chronic organ

GlobeNewswireMay 30 16:05 ET

Why Bank of Montreal Shares Are Trading Lower By Around 7%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session

Shares of Bank of Montreal (NYSE:BMO) fell sharply during Wednesday's session after the company reported worse-than-expected second-quarter financial results.Bank of Montreal posted quarterly adjusted

BenzingaMay 29 13:28 ET

Heico Posts Upbeat Earnings, Joins Surmodics, Abercrombie & Fitch And Other Big Stocks Moving Higher On Wednesday

U.S. stocks were lower, with the Dow Jones index falling more than 300 points on Wednesday.Shares of HEICO Corporation (NYSE:HEI) rose sharply during Wednesday's session following a second-quarter ear

BenzingaMay 29 10:38 ET

Express News | Gyre Therapeutics Expects Addition To Russell 2000 And Russell 3000 Indexes

BenzingaMay 28 16:15 ET

Gyre Therapeutics Announces Expected Addition to the Russell 2000 and Russell 3000 Indexes

SAN DIEGO, May 28, 2024 (GLOBE NEWSWIRE) -- Gyre Therapeutics ("Gyre") (NASDAQ:GYRE), a clinical-stage, self-sustainable biotechnology company developing anti-fibrotic therapeutics for a variety of chronic organ

GlobeNewswireMay 28 16:05 ET

Gyre Therapeutics | 10-Q: Quarterly report

SEC announcementMay 13 16:13 ET · Announcements

Gyre Therapeutics Reports First Quarter 2024 Earnings

Yahoo FinanceMay 11 08:25 ET

Express News | Gyre Therapeutics Inc: Qtrly Diluted Shr $0.03

ReutersMay 9 16:13 ET

Express News | Gyre Therapeutics Inc: Anticipates That Its Cash Resources as of March 31 Will Enable It to Fund Operations Through at Least 12 Months

ReutersMay 9 16:13 ET

Express News | Gyre Therapeutics Inc: U.S. Ind Submission to Evaluate F351 for Treatment of Nash-Associated Liver Fibrosis Expected in Late 2024

ReutersMay 9 16:12 ET

Express News | Gyre Therapeutics Q1 Operating Profit USD 8.1 Million

ReutersMay 9 16:10 ET

Express News | Gyre Therapeutics Q1 Net Income USD 9.9 Million

ReutersMay 9 16:10 ET

Express News | Gyre Therapeutics Q1 Revenue USD 26.9 Million

ReutersMay 9 16:10 ET

Express News | Gyre Therapeutics: On May 7, Got Into Comprehensive Agreement With Jiangsu Wangao to Buy Rights to Generic Drug Nintedanib

ReutersMay 8 08:10 ET

Gyre Therapeutics(GYRE.US) Director Sells US$282.58K in Common Stock

$Gyre Therapeutics(GYRE.US)$ Director USMAN NASSIM sold 20,000 shares of common stock on May 1, 2024 at an average price of $14.13 for a total value of $282.58K.Source: Announcement What is statement

moomoo NewsMay 2 19:03 ET

Form 144 | Gyre Therapeutics(GYRE.US) Director Proposes to Sell 282.47K in Common Stocks

SEC FILLINGS DISCLOSED/ May 1, $Gyre Therapeutics(GYRE.US)$ Director NASSIM USMAN intends to sell 20,000 shares of its common stock on May 1, with a total market value of approximately $282.47K. NAS

moomoo NewsMay 1 16:53 ET